Nephros, Inc.
NASDAQ Capital MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Robert Banks
- Full Time Employees
- 36
- Sector
- Healthcare
- Industry
- Medical - Instruments & Supplies
- Address
- 380 Lackawanna Place South Orange NJ United States of America 07079
- IPO Date
- Sep 21, 2004
- CIK
- 0001196298
- Website
- nephros.com
- Similar Companies
- Business
- Nephros, Inc. (Nasdaq: NEPH) develops and sells advanced water filtration and purification solutions to medical and commercial markets in the United States; its core offerings include FDA Class II medical ultrafilters and microfilters for infection control that retain bacteria, viruses, endotoxins, Legionella, and other opportunistic waterborne pathogens using proprietary 0.005-micron and 0.1-micron hollow-fiber technology; dialysis water filtration products that purify water and bicarbonate concentrate to meet ANSI/AAMI/ISO standards for hemodialysis applications; and commercial filtration cartridges and drop-ins that improve taste, odor, reduce scale, soluble lead, cysts, particulates, heavy metals, chemical compounds, and biofilm in food service, hospitality, convenience stores, health care facilities, ice machines, beverage dispensers, and hydration stations. Founded in 1997 and headquartered in South Orange, New Jersey, the company operates through medical water filtration and commercial water filtration segments, serving hospitals, dialysis centers, laboratories, manufacturing, military, outdoor recreation, and institutional customers with point-of-use solutions, water system evaluations, ice machine audits, emergency response services, and water-quality education. Nephros recently launched its 19-Series PFAS filter in October 2025 for point-of-use reduction of per- and polyfluoroalkyl substances in potable water to address regulatory-driven chemical contamination concerns; introduced the HydraGuard 20-inch UltraFilter to expand into medical device manufacturing and pharmaceutical production markets compliant with ANSI/AAMI ST108 standards; achieved record third-quarter 2025 net revenue of $4.8 million, up 35% year-over-year with 51% programmatic revenue growth and fourth consecutive quarter of profitability; and reported year-to-date 2025 net revenue of $14.1 million, up 37%, with $1.1 million net income, $5.2 million cash reserves, and zero debt.
Nephros to Participate in the “Health, Wellness & Longevity” Virtual Conference Presented by Maxim Group LLC on Wednesday, July 22nd at 10:00 a.m. ET
Nephros, Inc. (NEPH) Discusses Evolving Water Safety Strategies and Expansion Beyond Filtration Transcript
�Nephros Announces Inclusion in the Russell Microcap® Index
Nephros Announces Inclusion in the Russell Microcap® Index
Nephros to Host Virtual Investor Event: “Beyond Filtration: The Nephros Model in Action”
Nephros to Host Virtual Investor Event: “Beyond Filtration: The Nephros Model in Action”
Nephros Positions Ultrafiltration Technology as a Solution to Emerging Microplastic Risk in Water
Nephros, Inc. (NEPH) Q1 2026 Earnings Call Transcript
Nephros Announces Financial Results for Quarter Ended March 31, 2026
�Nephros Schedules First Quarter 2026 Financial Results Conference Call
Nephros Schedules First Quarter 2026 Financial Results Conference Call
Nephros Expands Strategic Focus in Greater New York Market with Dedicated Regional Leadership
Nephros Expands Strategic Focus in Greater New York Market with Dedicated Regional Leadership
�Nephros Expands Water Safety Capabilities With ASSE 12080 Certified Water Management Planning Expertise
Nephros Expands Water Safety Capabilities With ASSE 12080 Certified Water Management Planning Expertise
Reviewing Envista (NYSE:NVST) & Nephros (NASDAQ:NEPH)
Nephros, Inc. (NEPH) Q4 2025 Earnings Call Transcript
�Nephros Announces Fourth Quarter and Record Fiscal Year 2025 Financial Results
Nephros Announces Fourth Quarter and Record Fiscal Year 2025 Financial Results
�Nephros Schedules Fourth Quarter 2025 Financial Results Conference Call